Search

Your search keyword '"Limmroth, V."' showing total 24 results
Start Over Author "Limmroth, V." Database OAIster
24 results on '"Limmroth, V."'

1. Communication, Coordination, and Security for people with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol

Author

Golla, H, Dillen, K, Hellmich, M, Dojan, T, Ungeheuer, S, Schmalz, P, Staß, A, Mildenberger, V, Goereci, Y, Dunkl, V, Strupp, J, Fink, GR, Voltz, R, Stock, S, Cornely, OA, Stahmann, A, Müller, A, Löcherbach, P, Burghaus, L, Limmroth, V, Bonmann, E, Gerbershagen, K, Nelles, G, Joist, T, Haas, J, Temmes, H, Warnke, C, Golla, H, Dillen, K, Hellmich, M, Dojan, T, Ungeheuer, S, Schmalz, P, Staß, A, Mildenberger, V, Goereci, Y, Dunkl, V, Strupp, J, Fink, GR, Voltz, R, Stock, S, Cornely, OA, Stahmann, A, Müller, A, Löcherbach, P, Burghaus, L, Limmroth, V, Bonmann, E, Gerbershagen, K, Nelles, G, Joist, T, Haas, J, Temmes, H, and Warnke, C

Published
2021

2. Communication, Coordination, and Security for people with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol

Author

Golla, H, Dillen, K, Hellmich, M, Dojan, T, Ungeheuer, S, Schmalz, P, Staß, A, Mildenberger, V, Goereci, Y, Dunkl, V, Strupp, J, Fink, GR, Voltz, R, Stock, S, Cornely, OA, Stahmann, A, Müller, A, Löcherbach, P, Burghaus, L, Limmroth, V, Bonmann, E, Gerbershagen, K, Nelles, G, Joist, T, Haas, J, Temmes, H, Warnke, C, Golla, H, Dillen, K, Hellmich, M, Dojan, T, Ungeheuer, S, Schmalz, P, Staß, A, Mildenberger, V, Goereci, Y, Dunkl, V, Strupp, J, Fink, GR, Voltz, R, Stock, S, Cornely, OA, Stahmann, A, Müller, A, Löcherbach, P, Burghaus, L, Limmroth, V, Bonmann, E, Gerbershagen, K, Nelles, G, Joist, T, Haas, J, Temmes, H, and Warnke, C

Published
2021

3. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

Author

Comi, G, Alroughani, R, Boster, AL, Bass, AD, Berkovich, R, Fernandez, O, Kim, HJ, Limmroth, V, Lycke, J, Macdonell, RAL, Sharrack, B, Singer, BA, Vermersch, P, Wiendl, H, Ziemssen, T, Jacobs, A, Daizadeh, N, Rodriguez, CE, Traboulsee, A, Comi, G, Alroughani, R, Boster, AL, Bass, AD, Berkovich, R, Fernandez, O, Kim, HJ, Limmroth, V, Lycke, J, Macdonell, RAL, Sharrack, B, Singer, BA, Vermersch, P, Wiendl, H, Ziemssen, T, Jacobs, A, Daizadeh, N, Rodriguez, CE, and Traboulsee, A

Abstract

BACKGROUND: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. OBJECTIVE: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. METHODS: Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); <12-month follow-up after last alemtuzumab course. RESULTS: In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. CONCLUSION: Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.

Published
2020

4. TRUST-Study: Methods of an Optional MRI-Safety Surveillance for Progressive Multifocal Leukoencephalopathy (PML) in Relapsing-Remitting Multiple Sclerosis Patients Treated with Natalizumab

Author

Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O., Hartung, H-P, Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O., and Hartung, H-P

Published
2017

8. Autoinjector preference among patients with multiple sclerosis: results from a national survey

Author

Limmroth,V, Reischl,J, Mann,B, Morosov,X, Kokoschka,A, Weller,I, Schreiner,T, Limmroth,V, Reischl,J, Mann,B, Morosov,X, Kokoschka,A, Weller,I, and Schreiner,T

Abstract

V Limmroth,1 J Reischl,2 B Mann,3 X Morosov,2 A Kokoschka,2 I Weller,2 T Schreiner2 1Clinic for Neurology and Palliative Medicine, Municipal Hospital Köln-Merheim, Cologne, 2Bayer Vital GmbH, Leverkusen, 3IFAK Institute GmbH & Co. KG, Taunusstein, Germany Purpose: Autoinjectors are well-established in supporting multiple sclerosis (MS) therapy. This market survey was aimed at investigating patients’ rating of three devices for subcutaneous interferon beta formulations: the electronic autoinjectors Betaconnect® and RebiSmart™ as well as the mechanical ExtaviPro™ device. Patients and methods: Organization and conduction of structured face-to-face interviews in five German cities were managed through an independent external market research company. After questionnaire validation (n=15), 85 participants currently either using the Betaconnect (n=39), the RebiSmart (n=36) or the ExtaviPro injector (n=10) were asked 22 questions in the same order. First, patients named their current device in use, watched the corresponding instruction video, and were queried about their device. Second, patients were asked about their opinion of an ideal autoinjector. Third, instruction videos for the two non-used devices were presented and participants could dummy-inject into a pillow. Last, patients evaluated device features and indicated their preferred autoinjector. Results: Before having been presented the two other autoinjectors not in use, evaluation of patients’ satisfaction with their own device revealed that 82% of the Betaconnect users, 67% of the RebiSmart and 60% of the ExtaviPro users were highly satisfied. All patients desired some improvement of their own device particularly concerning optimization of size and handling. Subsequent to testing and watching instruction videos of all devices, the Betaconnect received the best rating regarding different functions. Finally, participants indicated their preferred auto

Published
2017

9. TRUST-Study: Methods of an Optional MRI-Safety Surveillance for Progressive Multifocal Leukoencephalopathy (PML) in Relapsing-Remitting Multiple Sclerosis Patients Treated with Natalizumab

Author

Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O., Hartung, H-P, Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O., and Hartung, H-P

Published
2017

13. Querschnittsyndrome

Author

Bewermeyer, H, Fink, G R, Limmroth, V, Bewermeyer, H ( H ), Fink, G R ( G R ), Limmroth, V ( V ), Nelles, G, Curt, A, Bewermeyer, H, Fink, G R, Limmroth, V, Bewermeyer, H ( H ), Fink, G R ( G R ), Limmroth, V ( V ), Nelles, G, and Curt, A

Published
2010

15. TRUST-Study: methods of an optional MRI-safety surveillance for progressive multifocal leukoencephalopathy (PML) in relapsing remitting multiple sclerosis patients treated with Natalizumab

Author

Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O., Hartung, H. -P., Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O., and Hartung, H. -P.

Published
2016

16. TRUST-Study: methods of an optional MRI-safety surveillance for progressive multifocal leukoencephalopathy (PML) in relapsing remitting multiple sclerosis patients treated with Natalizumab

Author

Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O., Hartung, H. -P., Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O., and Hartung, H. -P.

Published
2016

18. Kaufunktionsstörung – Myoarthropathie des Kausystems

Author

Agosti, Reto, Diener, Hans-Christoh, Limmroth, Volker, Agosti, R ( Reto ), Diener, H ( Hans-Christoh ), Limmroth, V ( Volker ), Ettlin, Dominik A; https://orcid.org/0000-0001-7353-073X, Gaul, Charly, Agosti, Reto, Diener, Hans-Christoh, Limmroth, Volker, Agosti, R ( Reto ), Diener, H ( Hans-Christoh ), Limmroth, V ( Volker ), Ettlin, Dominik A; https://orcid.org/0000-0001-7353-073X, and Gaul, Charly

Published
2015

19. Kaufunktionsstörung – Myoarthropathie des Kausystems

Author

Agosti, Reto, Diener, Hans-Christoh, Limmroth, Volker, Agosti, R ( Reto ), Diener, H ( Hans-Christoh ), Limmroth, V ( Volker ), Ettlin, Dominik A; https://orcid.org/0000-0001-7353-073X, Gaul, Charly, Agosti, Reto, Diener, Hans-Christoh, Limmroth, Volker, Agosti, R ( Reto ), Diener, H ( Hans-Christoh ), Limmroth, V ( Volker ), Ettlin, Dominik A; https://orcid.org/0000-0001-7353-073X, and Gaul, Charly

Published
2015

20. The CSF JCV antibody index for diagnosis of natalizumab-associated PML

Author

Warnke, C., von Geldern, G., Markwerth, P., Dehmel, T., Hoepner, R., Gold, R., Pawlita, M., Kuempfel, T., Maeurer, M., Stangel, M., Wegner, F., Hohlfeld, R., Straeten, V., Limmroth, V., Weber, T., Hermsen, D., Kleinschnitz, C., Hartung, H. -P, Wattjes, M. P., Svenningson, Anders, Major, E., Olsson, T., Kieseier, B. C., Adams, O., Warnke, C., von Geldern, G., Markwerth, P., Dehmel, T., Hoepner, R., Gold, R., Pawlita, M., Kuempfel, T., Maeurer, M., Stangel, M., Wegner, F., Hohlfeld, R., Straeten, V., Limmroth, V., Weber, T., Hermsen, D., Kleinschnitz, C., Hartung, H. -P, Wattjes, M. P., Svenningson, Anders, Major, E., Olsson, T., Kieseier, B. C., and Adams, O.

Published
2014

21. TRUST study design-a study to evaluate an integrated approach for optimized patient management in multiple sclerosis patients treated with natalizumab

Author

Hartung, H-P, Ziemssen, T., Bayas, A., Tackenberg, B., Wuerfel, J., Limmroth, V., Linker, R., Maeurer, M., Haas, J., Stangel, M., Harlin, O., Winterstein, C., Meergans, M., Wernsdoerfer, C., Gass, A., Hartung, H-P, Ziemssen, T., Bayas, A., Tackenberg, B., Wuerfel, J., Limmroth, V., Linker, R., Maeurer, M., Haas, J., Stangel, M., Harlin, O., Winterstein, C., Meergans, M., Wernsdoerfer, C., and Gass, A.

Published
2014

22. TRUST study design-a study to evaluate an integrated approach for optimized patient management in multiple sclerosis patients treated with natalizumab

Author

Hartung, H-P, Ziemssen, T., Bayas, A., Tackenberg, B., Wuerfel, J., Limmroth, V., Linker, R., Maeurer, M., Haas, J., Stangel, M., Harlin, O., Winterstein, C., Meergans, M., Wernsdoerfer, C., Gass, A., Hartung, H-P, Ziemssen, T., Bayas, A., Tackenberg, B., Wuerfel, J., Limmroth, V., Linker, R., Maeurer, M., Haas, J., Stangel, M., Harlin, O., Winterstein, C., Meergans, M., Wernsdoerfer, C., and Gass, A.

Published
2014

23. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults

Author

Silberstein, S., Tfelt-Hansen, P., Dodick, D.W., Limmroth, V., Lipton, R.B., Pascual, J., Wang, S.J., Silberstein, S., Tfelt-Hansen, P., Dodick, D.W., Limmroth, V., Lipton, R.B., Pascual, J., and Wang, S.J.

Abstract

In 1991 the Clinical Trials Subcommittee of the International Headache Society (IHS) developed and published its first edition of the Guidelines on controlled trials of drugs in episodic migraine because only quality trials can form the basis for international collaboration on drug therapy, and these Guidelines would 'improve the quality of controlled clinical trials in migraine'. With the current trend for large multinational trials, there is a need for increased awareness of methodological issues in clinical trials of drugs and other treatments for chronic migraine. These Guidelines are intended to assist in the design of well-controlled clinical trials of chronic migraine in adults, and do not apply to studies in children or adolescents Udgivelsesdato: 2008/5

Published
2008

24. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults

Author

Silberstein, S., Tfelt-Hansen, P., Dodick, D.W., Limmroth, V., Lipton, R.B., Pascual, J., Wang, S.J., Silberstein, S., Tfelt-Hansen, P., Dodick, D.W., Limmroth, V., Lipton, R.B., Pascual, J., and Wang, S.J.

Abstract

In 1991 the Clinical Trials Subcommittee of the International Headache Society (IHS) developed and published its first edition of the Guidelines on controlled trials of drugs in episodic migraine because only quality trials can form the basis for international collaboration on drug therapy, and these Guidelines would 'improve the quality of controlled clinical trials in migraine'. With the current trend for large multinational trials, there is a need for increased awareness of methodological issues in clinical trials of drugs and other treatments for chronic migraine. These Guidelines are intended to assist in the design of well-controlled clinical trials of chronic migraine in adults, and do not apply to studies in children or adolescents Udgivelsesdato: 2008/5

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results